Bearing Point Capital LLC Invests $2.05 Million in AstraZeneca PLC $AZNCF

Bearing Point Capital LLC bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,665 shares of the company’s stock, valued at approximately $2,047,000.

Several other large investors have also made changes to their positions in AZNCF. Saranac Partners Ltd purchased a new stake in shares of AstraZeneca during the third quarter worth approximately $876,000. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $46,000. Valley Wealth Managers Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $144,000. Hendley & Co. Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $11,373,000. Finally, L & S Advisors Inc purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $14,863,000. 40.87% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00. The stock has a 50 day moving average price of $187.10 and a 200 day moving average price of $185.26.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.